308 related articles for article (PubMed ID: 6303966)
1. Expression of the BLA antigen, defined by the monoclonal 38.13 antibody, on Burkitt lymphoma lines, lymphoblastoid cell lines, their hybrids and other B-cell lymphomas and leukemias.
Klein G; Manneborg-Sandlund A; Ehlin-Henriksson B; Godal T; Wiels J; Tursz T
Int J Cancer; 1983 May; 31(5):535-42. PubMed ID: 6303966
[TBL] [Abstract][Full Text] [Related]
2. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
Klein G; Ehlin-Henriksson B; Schlossman SF
J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody with anti-Burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines.
Wiels J; Lenoir GM; Fellous M; Lipinski M; Salomon JC; Tetaud C; Tursz T
Int J Cancer; 1982 Jun; 29(6):653-8. PubMed ID: 6286514
[TBL] [Abstract][Full Text] [Related]
4. Induction of cell differentiation in Burkitt lymphoma lines. BLA: a glycolipid marker of B-cell differentiation.
Balana A; Wiels J; Tetaud C; Mishal Z; Tursz T
Int J Cancer; 1985 Oct; 36(4):453-60. PubMed ID: 3930411
[TBL] [Abstract][Full Text] [Related]
5. Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.
Ehlin-Henriksson B; Manneborg-Sandlund A; Klein G
Int J Cancer; 1987 Feb; 39(2):211-8. PubMed ID: 3026973
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers.
Torsteinsdottir S; Masucci MG; Lenoir G; Klein G; Klein E
Cell Immunol; 1984 Jul; 86(2):278-86. PubMed ID: 6329520
[TBL] [Abstract][Full Text] [Related]
7. Distribution of the Burkitt's lymphoma-associated antigen (BLA) in normal human tissue and malignant lymphoma as defined by immunohistological staining with monoclonal antibody 38.13.
Pallesen G; Zeuthen J
J Cancer Res Clin Oncol; 1987; 113(1):78-86. PubMed ID: 3546331
[TBL] [Abstract][Full Text] [Related]
8. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype.
Falk MH; Trauth BC; Debatin KM; Klas C; Gregory CD; Rickinson AB; Calender A; Lenoir GM; Ellwart JW; Krammer PH
Blood; 1992 Jun; 79(12):3300-6. PubMed ID: 1375849
[TBL] [Abstract][Full Text] [Related]
9. A phenotypic study of cells from Burkitt lymphoma and EBV-B-lymphoblastoid lines and their relationship to cells in normal lymphoid tissues.
Ling NR; Hardie D; Lowe J; Johnson GD; Khan M; MacLennan IC
Int J Cancer; 1989 Jan; 43(1):112-8. PubMed ID: 2536003
[TBL] [Abstract][Full Text] [Related]
10. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.
Yokochi T; Holly RD; Clark EA
J Immunol; 1982 Feb; 128(2):823-7. PubMed ID: 6274961
[TBL] [Abstract][Full Text] [Related]
11. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.
Torsteinsdottir S; Masucci MG; Ehlin-Henriksson B; Brautbar C; Ben Bassat H; Klein G; Klein E
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5620-4. PubMed ID: 3016710
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody against a Burkitt lymphoma-associated antigen.
Wiels J; Fellous M; Tursz T
Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6485-8. PubMed ID: 7031655
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha up-regulates the expression of HLA class I determinants in Burkitt lymphoma lines.
Avila-Carino J; Torsteinsdottir S; Bejarano MT; Klein G; Klein E; Masucci MG
Cell Immunol; 1988 Dec; 117(2):303-11. PubMed ID: 2848629
[TBL] [Abstract][Full Text] [Related]
14. Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells.
Murray LJ; Habeshaw JA; Wiels J; Greaves MF
Int J Cancer; 1985 Nov; 36(5):561-5. PubMed ID: 3877000
[TBL] [Abstract][Full Text] [Related]
15. Human B-lymphoid cell lines.
Nilsson K
Hum Cell; 1992 Mar; 5(1):25-41. PubMed ID: 1329931
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody studies in B(non-T)-cell malignancies.
Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M
Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373
[TBL] [Abstract][Full Text] [Related]
17. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus.
Gregory CD; Edwards CF; Milner A; Wiels J; Lipinski M; Rowe M; Tursz T; Rickinson AB
Int J Cancer; 1988 Aug; 42(2):213-20. PubMed ID: 2841246
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of marker expression in B-cell leukemias and its diagnostic significance.
Menon M; Drexler HG; Minowada J
Leuk Res; 1986; 10(1):25-8. PubMed ID: 3080642
[TBL] [Abstract][Full Text] [Related]
19. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
Fresen KO; zur Hausen H
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
